Ultragenyx Pharmaceutical Inc. (RARE) Stock Price & Analysis
Ultragenyx Pharmaceutical Inc. (RARE) rose 5.56% to USD 22.79 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.
RARE last closed at USD 21.59; the session ranged USD 22.04–23.05 on volume of 1,560,055 shares. Market capitalization is $2.24B, with a 52-week range of USD 18.29–42.37 (NMS). Source: Nexqual, June 10, 2026 at 00:44 UTC.
Key Statistics (as of June 10, 2026 at 00:44 UTC)
| Price | USD 22.79 |
|---|---|
| Change | ▲ 5.56% (up) |
| Previous Close | USD 21.59 |
| Open | USD 22.14 |
| Day Range | USD 22.04 – 23.05 |
| 52-Week Range | USD 18.29 – 42.37 |
| Volume | 1,560,055 shares |
| Market Cap | $2.24B |
| Exchange | NMS |
Technical Analysis (RARE)
Nexqual's technical model rates RARE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46 (neutral) |
| vs SMA50 | Below (USD 23.87) |
| MACD | -0.56 (negative) |
Analyst Ratings (RARE)
Wall Street analysts rate RARE "None" based on 19 analysts, with a mean price target of USD 52.05 (range USD 25–96), per Nexqual as of June 10, 2026 at 00:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 52.05 |
| High Target | USD 96 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 17 / 2 / 0 |
Earnings (RARE)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1.14 |
| Revenue Estimate | $181.72M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.54 vs est -1.46 ▼ miss |
| 2025-12-31 | USD -1.29 vs est -1.17 ▼ miss |
| 2025-09-30 | USD -1.81 vs est -1.21 ▼ miss |
| 2025-06-30 | USD -1.17 vs est -1.32 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financials & Fundamentals (RARE)
| Total Revenue | $670.00M |
|---|---|
| Revenue Growth (YoY) | -2.20% |
| Gross Margin | -28.06% |
| Operating Margin | -102.21% |
| Profit Margin | -90.90% |
| Current Ratio | 2.02 |
| Total Cash | $413.00M |
| Total Debt | $1.20B |
| Free Cash Flow | $-219.09M |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financial Health Score (RARE)
Nexqual rates Ultragenyx Pharmaceutical Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:44 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $413M cash vs $1.20B debt |
| Cash Flow | Weak — FCF negative: -$219M, burning cash |
| Efficiency | Mixed — No data |
Ownership (RARE)
| Insider Ownership | +3.46% |
|---|---|
| Institutional Ownership | +104.11% |
| Shares Outstanding | 98.49M |
| Float | 94.50M |
| Short % of Float | +14.68% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Leadership (RARE)
Ultragenyx Pharmaceutical Inc. is led by Emil D. Kakkis (age 65), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:44 UTC.
| Founder, President, CEO & Director | Emil D. Kakkis (age 65) |
|---|---|
| Executive VP of Corporate Strategy & CFO | Howard Horn (age 46) |
| Senior Vice President of Business Development & Alliance Management | Vimal Srivastava (age 60) |
Major Backers & Investors (RARE)
Notable institutional backers of Ultragenyx Pharmaceutical Inc. include AQR Capital Management, LLC, RTW Investments LP, Sands Capital Management, LLC, according to Nexqual as of June 10, 2026 at 00:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 4.65% |
| RTW Investments LP | 3.7% |
| Sands Capital Management, LLC | 3.26% |
| Sofinnova Investments, Inc. | 3.19% |
| Wellington Management | 2.68% |
| Bellevue Group AG | 2.42% |
| AQR Funds-AQR Long-Short Equity Fund | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.7% |
| State Street | 8.63% |
| BlackRock | 8.1% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
From Ultragenyx Pharmaceutical Inc.'s Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
- Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
- Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
| QURE | uniQure N.V. | USD 26.46 | ▲ 0.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.